# Nathan Fowler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nathan-fowler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,779 |
| Field | Lymphoma Diagnosis and Treatment |
| h-index | 64 |
| i10-index | 211 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5044284041 |
| ORCID iD | https://orcid.org/0000-0002-9494-1877 |
| Works | 585 |

## Researcher papers

- [Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas](https://scholariq.org/papers/characteristics-of-anti-cd19-car-t-cell-infusion-products-associated-with/)
- [Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma](https://scholariq.org/papers/rituximab-plus-lenalidomide-in-advanced-untreated-follicular-lymphoma/)
- [Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial](https://scholariq.org/papers/lenalidomide-in-combination-with-rituximab-for-patients-with-relapsed-or/)

## Researcher topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Viral-associated cancers and disorders](https://scholariq.org/topics/viral-associated-cancers-and-disorders-2/)
- [CNS Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/cns-lymphoma-diagnosis-and-treatment/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.
